Skip to main content

Table 2 Laboratory parameters

From: A set of serum markers detecting systemic inflammation in psoriatic skin, entheseal, and joint disease in the absence of C-reactive protein and its link to clinical disease manifestations

HC

S

E

A

SE

SA

EA

SEA

N = 105

N = 105

  

N = 15

N = 15

N = 15

N = 15

N = 15

N = 15

N = 15

CRP

3.1 ± 0.1

3.4 ± 0.3

3.1 ± 0.3

6.4 ± 1.6***

3.0 ± 0.3

5.2 ± 0.9***

5.5 ± 1.1***

6.7 ± 1.4***

LC2

8.7 ± 0.5

86 ± 14***

44 ± 7***

33 ± 6***

93 ± 18***

71 ± 10***

50 ± 6***

76 ± 11***

BD2

0.4 ± 0.1

10 ± 2.8***

2.4 ± 0.4***

1.5 ± 1.4***

10 ± 2.7***

9.9 ± 2.2***

1.7 ± 0.4***

9.3 ± 3.1***

IL-22

8.6 ± 0.2

19 ± 2.6***

20 ± 2.6***

13 ± 2.3***

17.4 ± 1.7***

29 ± 5.5***

27 ± 3.8***

41 ± 5.6***

IL-8

4.4 ± 0.1

11 ± 2.2***

10 ± 1.3***

25 ± 6.9***

14 ± 2.1***

18 ± 4.1***

20 ± 5.0***

25 ± 6.6***

CP

1.3 ± 0.1

3.9 ± 0.5***

4.4 ± 0.6***

8.2 ± 1.0***

4.9 ± 0.6***

10 ± 1.6***

7.2 ± 1.3***

8.5 ± 1.6***

  1. HC healthy controls; monomorphic psoriatic disease manifestations: S skin disease, E enthesitis, A: arthritis; polymorphic psoriatic disease manifestations: SE skin disease + enthesitis, SA skin disease + arthritis, EA enthesitis + arthritis, SEA skin + enthesitis + arthritis, CRP C-reactive protein, LC2 lipocalin 2, BD2 beta-defensin 2, IL interleukin, CP calprotectin and IL-8. All values indicate means ± SEM. Asterisks indicate significances (p < 0.01) compared to healthy controls
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us